NHS Greater Glasgow & Clyde Area Drug and Therapeutics Committee
Greater Glasgow and Clyde Medicines
Medicines Update

PostScript 79 (Jan 2014) Updates

New NHSGGC guidelines

The following guidelines have been added to the repository on Staffnet

 

PostScript Extra Type 2 Diabetes

A new PostScript Extra bulletin on the pharmacological management of adult patients with type 2 diabetes is available here. This bulletin is an educational resource on the pharmacological management of type 2 diabetes.  Appendix 1 provides a summary of pharmacology, licensed indications, and formulary status of antidiabetic medicines. See Appendix 2 for an overview of the different types of insulin, insulin devices and their Formulary status. Refer to the GGC Diabetes guideline for further details and information on how to manage individual patients.

 

ADTC decisions summary

See here for full list of medicines and details of indications and restrictions.

 

Some additions to the Adult Total Formulary:

  • Atomoxetine (Strattera®) for attention-deficit/hyperactivity disorder in adults as part of a comprehensive treatment programme restricted to specialist initiation.
  • Axitinib (Inlyta®) for adult patients with advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine. Restricted to specialist use in accordance with regional protocol.
  • Enzalutamide (Xtandi®) for adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy. Restricted to specialist use in accordance with regional protocol.
  • Mannitol inhaled (Bronchitol®) for the treatment of cystic fibrosis (CF) in adults aged 18 years and above as an add-on therapy to best standard of care. Restricted to specialist initiation for patients who are not currently using dornase alfa due to lack of response, intolerance or ineligibility and have rapidly declining lung function and in whom other osmotic agents are considered unsuitable.
  • Vemurafenib (Zelboraf®) as monotherapy for adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. Restricted to specialist use for first-line treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma pending regional protocol.

 

The following medicine was among those added to the Paediatric Formulary

  • Ondansetron orodispersible films (Setofilm®) for chemotherapy-induced nausea and vomiting in children aged ≥6 months and prophylaxis and treatment of post-operative nausea and vomiting in children aged ≥4 years. Restricted to specialist initiation in patients with enhanced risk of aspiration or swallowing difficulties.

 

Previous article: Nalmefene for alcohol withdrawal